Bristol-Myers Squibb has acquired privately held Cormorant Pharmaceuticals. According to the company, the transaction included upfront, as well as near term contingent milestone payments of a maximum of $95 million and additional contingent consideration of a maximum of $425 million upon the achievement of some development and regulatory milestones. The acquisition provides BMS with complete rights to Cormorant’s HuMax-IL8 antibody program and the lead candidate HuMax-IL8, a Phase 1/2 m...